Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

How I’m helping to #BreakTheBias: International Women’s Day

What do you think of when you imagine a scientist? Who do you see in a lab coat? Gender stereotypes and assumptions are rife and, as a child, the thought...

Extraordinary lives: advancing change in rare diseases

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. On this day across the globe, the rare...

Extraordinary lives: advancing change in rare diseases

We are extending the conversation for Rare Disease Day by continuing to raise awareness and generate change for the 300 million people worldwide living with a rare disease, their families...

Placing people at Lucid’s heart: Paul Cutler, Lucid Group’s new Chief People Officer

We interviewed Paul Cutler, Lucid Group’s new Chief People Officer, to find out a bit more about what makes him tick, why he chose to join Lucid, and what his...

A Lucid Group social

The newly formed Lucid Social Committee is launching its first event for the year: Today, on Thursday 24 February Lucid will be hosting its inaugural board games night in both...

Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy

We are excited to welcome this year’s cohort of graduates into our Lucid Futures Academy, which is now into its sixth year after being launched in Oct 2017.The Futures Academy...

We let your whole self shine

People are at the heart of who we are. Our aim is to transform the lives of those we touch without prejudice or discrimination. At Lucid, the magic we create...

Climbing my own Lucid Ladder

Transforming lives. That’s what Lucid is all about. I knew that even before I stepped through the fabled door of ‘Towers’ on a chilly January morning in 2019. It’s why...

A Lucid Thirsty Thursday D&I Special

Last week’s ‘Thirsty Thursday’ session was organised by the Lucid Group D&I Committee, whose goal is to foster a culture where diversity and inclusivity are embedded and practised within all...

Connecting capabilities in healthcare communications

The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...